A5010658926- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
- Reproductive Biology and Fertility
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Ovarian function and disorders
- Prenatal Screening and Diagnostics
- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Family Support in Illness
- Breast Lesions and Carcinomas
- PARP inhibition in cancer therapy
- Cancer-related cognitive impairment studies
- Global Cancer Incidence and Screening
- Male Breast Health Studies
- Glioma Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Reproductive System and Pregnancy
- Chromatin Remodeling and Cancer
Dana-Farber Cancer Institute
2015-2025
Harvard University
2012-2024
Dana-Farber Brigham Cancer Center
2012-2024
Breast Cancer Research Foundation
2023
Conquer Cancer Foundation
2023
Susan G. Komen Breast Cancer Foundation
2023
Brigham and Women's Hospital
2012-2021
Mass General Brigham
2014
University of Pennsylvania
2013
Boston Children's Hospital
2013
<h3>Importance</h3> Young women with breast cancer are increasingly choosing bilateral mastectomy (BM), yet little is known about short-term and long-term physical psychosocial well-being following surgery in this population. <h3>Objective</h3> To evaluate the differential associations of quality life (QOL) outcomes from 1 to 5 years diagnosis. <h3>Design, Setting, Participants</h3> Cohort study <h3>Setting</h3> Multicenter, including academic community hospitals North America...
Young women with germline BRCA mutations have unique reproductive challenges. Pregnancy after breast cancer does not increase the risk of recurrence; however, very limited data are available in patients mutations. This study investigated impact pregnancy on outcomes mutations.This is an international, multicenter, hospital-based, retrospective cohort study. Eligible were diagnosed between January 2000 and December 2012 invasive early at age ≤ 40 years harbored deleterious Primary end points...
Background Fear of cancer recurrence (FCR) is more intense in younger women. Because FCR a powerful determinant quality life, identifying those at risk for persistently elevated can inform timing interventions. Methods A total 965 women with stage 0 to III breast enrolled the Young Women's Breast Cancer Study, prospective cohort diagnosed age ≤40 years, completed 3‐item Lasry Recurrence Index. Group‐based trajectory modeling was used classify distinct patterns from baseline through 5 years...
The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer used to inform recommendations for chemotherapy. Women ≤ 40 years of age represent a minority patients studied using gene expression profiles.The Young Women's Breast Cancer Study prospective cohort diagnosed at enrolled between 2006 2016 (N = 1,302). We identified stage I-III ER+/HER2- cancer. RS was...
Abstract De-escalating adjuvant therapy following pathologic complete response (pCR) to an abbreviated neoadjuvant regimen in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is the focus of international research efforts. However, feasibility this approach and its appeal patients providers had not been formally investigated. We aimed assess adherence de-escalated antibody doublet (trastuzumab pertuzumab [HP], without chemotherapy) among with pCR paclitaxel/HP (THP)....
Young age at breast cancer diagnosis correlates with unfavorable clinicopathologic features and worse outcomes compared older women. Understanding biological differences between tumors in young versus women may lead to better therapeutic approaches for younger patients.We identified 100 patients ≤35 years old nonmetastatic who participated the prospective Women's Breast Cancer Study cohort. Tumors were assigned a surrogate intrinsic subtype based on receptor status grade. Whole-exome...
Background The diagnosis and treatment of breast cancer can have profound effects on a young woman's family planning fertility, particularly among women with hormone receptor–positive cancer. Methods Young Women's Breast Cancer Study was multicenter cohort aged 40 years or younger newly diagnosed from 2006 to 2016. Surveys included assessments fertility concerns, endocrine therapy (ET) preferences, use. Characteristics were compared between who reported that concerns affected ET decisions...
Background Proton beam therapy (PBT) for pediatric CNS malignancies may reduce late toxicity, but acute toxicity is not well defined. We examined children with treated PBT. Procedure conducted a retrospective review of 48 malignant brain tumors PBT at our facility from 2010 to 2012. For each patient, we recorded age diagnosis, tumor location, histologic subtype, radiation dose, extent radiation, and use concurrent chemotherapy. Acute scores were per the National Cancer Institute Common...
Abstract Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant ( mBRCA ) have similar outcomes as non-carriers. However, the impact of type gene BRCA1 vs. BRCA2 and hormone receptor status (positive [HR+] negative [HR−]) on clinical behavior BC remains largely unknown. This is an international, multicenter, hospital-based, retrospective cohort study that included diagnosed, between January 2000 December 2012, with stage I–III invasive early at age ≤40 years. From 30...
Purpose Compared with older women diagnosed breast cancer, younger are more likely to die of cancer and suffer psychosocially in both the short-term long term. The Young Women’s Breast Cancer Study (YWS) is a multisite prospective cohort study established address gaps our knowledge about this vulnerable understudied population. Participants YWS enrolled 1302 newly stages 0–IV at age 40 years or 13 academic community sites North America between 2006 2016. Longitudinal patient-reported outcome...
Many young women with newly diagnosed breast cancer are interested in future pregnancies. Prospective data regarding fertility interest and reproductive patterns after diagnosis needed to counsel patients.The Young Women's Breast Cancer Study is a multicenter, prospective cohort of who were at age ≤40 years between 2006 2016. Women complete surveys baseline, every 6 months for 3 years, then annually. Here, the authors describe pregnancies within 5 stage 0 through III cancer.Of 1026 eligible...
Background Weight gain after a breast cancer diagnosis is common and associated with inferior outcomes. Young survivors may be especially susceptible to weight changes given the impact of treatment on menopausal status. Methods The authors identified women who were diagnosed stage 0 III at age 40 years or younger between 2006 2016 from multicenter prospective cohort. Self‐reported was collected 1 year 3 postdiagnosis. Tumor data obtained medical records patient surveys. Multinomial logistic...
Abstract Introduction: CDK4/6i improve survival in HR+ MBC but efficacy is limited by mechanisms of resistance including MAPK pathway activation. Avutometinib (VS-6766), a RAF/MEK inhibitor, may reverse resistance, and enhances abema’s anti-proliferative effect preclinical studies. The safety tolerability avutometinib combined with abema fulvestrant unknown. Methods: Eligible pts had HR+/HER2- MBC, prior progression on CDK4/6i, measurable/evaluable disease. Prior was allowed not required....
Abstract Young women with breast cancer experience unique treatment and survivorship issues centering on treatment-related amenorrhea (TRA), including fertility preservation management of ovarian function as endocrine therapy. The Women’s Breast Cancer Study (YWS) is a multi-center, prospective cohort study diagnosed at age ≤40, enrolled from 2006 to 2016. Menstrual outcomes were self-reported serial surveys. We evaluated factors associated TRA using logistic regression. One year...
Many young women with breast cancer undergo fertility preservation (FP) before treatment. This study examined the impact of FP on outcomes.The authors performed a retrospective cohort 272 aged 20 to 45 years newly diagnosed stage 0 III who underwent an consultation between 2005 and 2017. Among these women, 123 (45.2%) (fertility preservation-positive [FP+]). The remaining 149 did not preservation-negative [FP-]).The characteristics at enrollment were similar exception ethnicity (FP+, 87.8%...
Objective: We aimed to investigate eligibility for breast conserving surgery (BCS) pre- and post-neoadjuvant systemic therapy (NST), trends in the surgical treatment of young cancer patients. Background: Young women with are more likely present larger tumors aggressive phenotypes, may benefit from NST. Little is known about how response NST influences decisions women. Methods: The Women's Breast Cancer Study, a multicenter prospective cohort diagnosed at age ≤40, enrolled 1302 patients 2006...